2022 Announcements

CLINUVEL
Posted by CLINUVEL
July 22, 2022

CLINUVEL Kommuniqué III

Seit dem News Communiqué II vom 31. März 2022 hat das Unternehmen...

Read More
CLINUVEL
Posted by CLINUVEL
June 23, 2022

Change of Director’s Interest Notice

Melbourne, Australia, 23 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
June 23, 2022

CLINUVEL Communiqué III

Since News Communiqué II on 31 March 2022, the Company has reported...

Read More
CLINUVEL
Posted by CLINUVEL
June 14, 2022

Change of Director’s Interest Notice

Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
June 14, 2022

Notice of ceasing to be a substantial holder

Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
June 10, 2022

Jeffries Healthcare Conference June 2022

CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the Jeffries Healthcare...

Read More
CLINUVEL
Posted by CLINUVEL
May 26, 2022

H.C. Wainwright Global Investment Conference 2022

CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...

Read More
CLINUVEL
Posted by CLINUVEL
May 25, 2022

Notice of change of interests of initial substantial holder

Melbourne, Australia, 25 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 20, 2022

Notice of initial substantial holder

Melbourne, Australia, 20 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 13, 2022

Strategic Update IV

CLINUVEL today announced its fourth Strategic Update, focused on the Group’s view...

Read More
CLINUVEL
Posted by CLINUVEL
May 12, 2022

Change of Director’s Interest Notice

Melbourne, Australia, 12 May 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 10, 2022

CLINUVEL progresses vitiligo treatment program

A new potential therapy for the pigment loss disorder vitiligo will undergo...

Read More
CLINUVEL
Posted by CLINUVEL
May 10, 2022

CLINUVEL progresses vitiligo study

CLINUVEL today announced that it will start treatment of vitiligo patients with...

Read More
CLINUVEL
Posted by CLINUVEL
May 6, 2022

Notification regarding unquoted securities

Melbourne, Australia, 6 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 4, 2022

Positive final results in stroke

CLINUVEL today released positive final results of the open label pilot study...

Read More